FROM THE LITERATURE

Peripheral Eosinophils and Eosinophilic Esophagitis

Read Article

Eosinophilic esophagitis (EoE) is a chronic inflammatory disease associated with mucosal infiltration of the esophagus. EoE incidence appears to be increasing, especially in children, and repeat esophagogastroduodenoscopy (EGD) often is needed to confirm therapeutic response to EoE (typically topical mucosal steroid therapy or dietary changes directed at preventing allergic disease). Since clinical symptoms of EoE are not a good indicator of clinical response to therapy, one of the current goals in EoE research is to find non-invasive biomarkers to monitor disease activity. In that regard, the blood eosinophil count has the potential to be such a marker

The authors of this study performed a retrospective chart review of all pediatric patients (less than 18 years of age) diagnosed with EoE over a 7-year period. Patients with coexisting GI disease were excluded, and EoE was defined as an eosinophil count greater than or equal to 15 eosinophils per highpower field (HPF) in biopsies in any of 3 regions of the esophagus (lower, mid, upper). All patients in this group had been on a proton pump inhibitor for at least 4 weeks prior to EGD. The primary study endpoint was determination of a possible correlation between absolute peripheral eosinophil count and esophageal eosinophilic infiltration. The secondary study endpoint was to see if esophageal eosinophils correlated with biopsy findings of basilar hyperplasia, spongiosis, and the presence of neutrophils and lymphocytes.

A total of 57 patients with EoE, 91 EGDs, and 279 biopsy specimens were included in the study. The oldest patient in the study was 17.9 years while the youngest patient was 1.6 years. The age of participants ranged from 1.6 years to 17.9 years of age, and white study subjects comprised 80% of the study population. A total of 66 procedures (71%) had biopsies consistent with EoE while the other 29% had less than 15 eosinophils per HPF or had no disease noted on biopsies. A significant correlation was seen between absolute eosinophil counts in blood samples and highest esophageal counts in biopsy specimens (P=0.0009). There was a significant correlation between absolute eosinophil counts in patients with active EoE compared to patients with biopsies showing less than 15 eosinophils per HPF or no eosinophilic infiltration. An absolute eosinophil count less than 500 correlated well with patients with inactive disease although an absolute eosinophil count greater than 500 did not correlate well with active EoE. However, when using a logistic regression model for race, sex, weight, height, and body mass index (BMI), none of these factors correlated with absolute eosinophil counts in relation to EoE activity.

It was noted that 58.1% of patients with EoE had allergic rhinitis, 50.5% of patients had food allergies, 38% had asthma, 29 % had eczema, and 14% had all of these conditions together. The most common symptoms included odynophagia (6.5%), food impaction (7.5%), chest pain (11.8%), nausea (23.7%), gastroesophageal reflux symptoms (24.7%), emesis (24.7%), dysphagia (25.8%), and abdominal pain (33.3%). The most common endoscopic finding in patients with EoE included esophageal furrowing (43%). Basilar hyperplasia, spongiosis, and microabscesses were significantly more common in patients with EoE compared to patients with no EoE although the presence of lymphocytes and neutrophils in biopsies did not differ between groups.

Although absolute eosinophil count may be a marker for inactive EoE which has the potential to be used for disease response, this study showed that it was difficult to correlate such findings with worsening EoE. Basilar hyperplasia, spongiosis, and microabscesses (potential early markers of the development of fibrosis) did seem to correlate with EoE although infiltration of other cell types (neutrophils, lymphocytes) did not. The authors state that the patients with EoE in this study were all treated with swallowed budesonide, and we have no data on other interventions such as swallowed fluticasone or dietary therapy. It appears that absolute eosinophil count is not a good marker for following EoE activity over time.

Choudhury S., Kozielski R., Hua J., Wilding G., Baker S. Do histological features of eosinophilic esophagitis in children correlate with peripheral eosinophils? Journal of Pediatric Gastroenterology and Nutrition 2020; 70: 604-607.

Download Tables, Images & References

FELLOWS’ CORNER

A Case of Small Bowel Lipoma Presenting with Intussusception

Read Article

CASE PRESENTATION

A 55-year-old female was referred to gastroenterology service with severe and intermittent epigastric abdominal pain of 2 weeks duration. She had unintentional weight loss of 15 lbs. The pain was not associated with food intake. She had no prior abdominal surgeries. Her medical history was significant for arterial hypertension and diabetes mellitus. Physical examination revealed normal vital signs and epigastric tenderness with no palpable mass.

A complete blood count and chemistry panel were normal. An upper endoscopy and colonoscopy revealed no apparent cause of her symptoms but were remarkable for mild gastritis, diverticulosis, and small hemorrhoids. A contrastenhanced CT scan of the abdomen and pelvis showed small bowel intussusception in the right lower quadrant in mid-ileum as shown in Figure 1. For better visualization of small bowel, CT enterography was done (Figure 2) which confirmed the intussusception. An anterograde single balloon enteroscopy was unsuccessful in reaching the site of the intussusception. Surgical resection was arranged.

QUESTIONS

  1. What are the clinical manifestations of small bowel intussusception in adults?
  2. What are the causes of small bowel intussusception?
  3. What are the gastrointestinal manifestations of lipomas?
  4. What is the radiological diagnosis?

What are the Clinical Manifestations of Small Bowel Intussusception in Adults?

Intussusception is the telescoping of a proximal segment of the intestine into an adjacent distal segment. In a retrospective study,1 abdominal pain was the most frequently reported symptom (79%). The mean duration of acute pain was 4 hours, and 80% described an intermittent and cramping pain. Other described symptoms include vomiting and diarrhea. Bloody stool and a palpable mass are frequently seen in the pediatric population, however very uncommon in adults.

What are the Causes of Small Bowel Intussusception?

According to a recent meta-analysis,2 the common causes of intussusception in adults include benign tumors, followed by malignant tumors and idiopathic causes. The most common malignancies in enteric intussusception were metastatic carcinoma, metastatic lymphoma, and gastrointestinal stromal tumor (GIST). Benign tumors that can cause enteric intussusception include hamartoma, hemangioma, polyp (inflammatory, Peutz-Jegher), lipoma, and neurofibroma. These small bowel tumors typically result in lead-point for intussusception as shown in our case.

Non-lead point intussusception has been associated with celiac disease and Crohn’s disease. Inflammation with wall thickening and decreased or dysrhythmic small-bowel motility have been the suggested underlying mechanisms of intussusception.3,4

What are the Gastrointestinal Manifestations of Lipomas?

Lipomas are submucosal tumors that can grow in any part of the gastrointestinal tract and up to 20-25%5 are found in the small bowel. Most commonly lipomas are asymptomatic and found incidentally during endoscopic procedures. When symptomatic, they may have pseudopedicle that leads to intussusception. At times, they can ulcerate and cause anemia due to microscopic blood loss.

What is the Radiological Diagnosis?

The imaging modalities to assess intussusception include CT scan, ultrasound, and barium enema. The accuracy of the CT scan is varied widely, and has been reported to be 58-100%6 and is the preferred initial test of choice. Classic findings on CT scan include the target, bulls-eye, or sausageshaped lesions. When compared to a regular CT scan, CT enterography uses thinner sections and a large amount of low-density enteric contrast. CT enterography better depicts the small bowel wall and lumen making it a superior tool to assess small bowel neoplasms with a sensitivity of 84% and specificity of 96.9%.7

In our case, the CT scan of the abdomen showed small bowel intussusception involving a 12 cm segment within the right abdomen, with the characteristic sausage-shaped appearance (Figure 1). The CT enterography showed small bowel intussusception in the mid ileum and the lead point was a lipoma which measured 23 x 29 x 16 mm (Figure 2). The small bowel lipoma was not evident on the contrast-enhanced CT scan of the abdomen and single balloon enteroscopy.

References

  1. Cochran AA, Higgins GL, 3rd, Strout TD. Intussusception in traditional pediatric, nontraditional pediatric, and adult patients. Am J Emerg Med. 2011;29(5):523-527.
  2. Hong KD, Kim J, Ji W, Wexner SD. Adult intussusception: a systematic review and meta-analysis. Tech Coloproctol. 2019;23(4):315-324.
  3. Gonda TA, Khan SU, Cheng J, Lewis SK, Rubin M, Green PH. Association of intussusception and celiac disease in adults. Dig Dis Sci. 2010;55(10):2899-2903.
  4. Lopez-Tomassetti Fernandez EM, Lorenzo Rocha N, Arteaga Gonzalez I, Carrillo Pallares A. Ileoileal intussusception as initial manifestation of Crohn’s disease. Mcgill J Med. 2006;9(1):34-37.
  5. Thompson WM. Imaging and findings of lipomas of the gastrointestinal tract. AJR Am J Roentgenol. 2005;184(4):1163-1171.
  6. Marsicovetere P, Ivatury SJ, White B, Holubar SD. Intestinal Intussusception: Etiology, Diagnosis, and Treatment. Clin Colon Rectal Surg. 2017;30(1):30-39.
  7. Ilangovan R, Burling D, George A, Gupta A, Marshall M, Taylor SA. CT enterography: review of technique and practical tips. Br J Radiol. 2012;85(1015):876-886.

Download Tables, Images & References

MEDICAL BULLETIN BOARD

Research Update: Icureceliac Patient Registry Leads to New Research Findings

Read Article

With your generous support, we invest heavily in celiac disease research to accelerate diagnosis, the development of treatments, and a cure. One of our most important research investments over the last several years has been in iCureCeliac®, the nation’s leading celiac disease patient registry. Again and again, iCureCeliac® has helped researchers from around the world develop a greater understanding of celiac disease, leading to investment in promising interventions and therapeutics.

In October, researchers published three important studies about celiac disease that used the iCureCeliac® patient registry database as the data source. I am pleased to be able to share these studies with you.

The first study was published in the Journal of American Medical Association (JAMA) and is titled Prevalence of Dermatitis Herpetiformis Within the iCureCeliac Patient-Powered Research NetworkPatient Characteristics and Dietary Counseling. Results of the University of Pennsylvania study showed patients with dermatitis herpetiformis (DH) were less likely to recall receiving counseling on a gluten-free diet at the time of diagnosis when compared with patients with celiac disease but without DH. This is likely because only 20% of patients diagnosed with DH present with classic GI symptoms associated with celiac disease at the time of diagnosis. As well, most DH diagnoses are made by dermatologists who may lack appreciation of the need to offer counseling on the gluten-free diet. As a result, DH patients who fail to adopt a strict glutenfree diet within the first 5 years of diagnosis may have an increased risk of mortality from lymphoma in this period of time.

The second study, Disease burden and quality of life impacts in patients with celiac disease on a gluten-free diet: an analysis of the iCureCeliac registry, was presented as a poster at the United European Gastroenterology Week Virtual 2020 Congress, October 11-13, 2020 and at the American College of Gastroenterology 2020 Virtual Annual Scientific Meeting, October 23-28. Authored by researchers from Takeda Pharmaceuticals and the Celiac Disease Foundation, the study presents compelling evidence that, ‘despite gluten-free diet adherence, many patients with celiac disease still have symptoms that substantially impact their lives. This was seen for all patients but was most pronounced for those with higher symptom burden, highlighting the heterogeneity of celiac disease burden and need for further therapies beyond a gluten-free diet.’ Takeda currently has two celiac disease drugs in development, TAK-101, which is designed to promote immune intolerance, and TAK062, which works by enzymatically digesting gluten. Findings from iCureCeliac® continue to substantiate the need for treatment alternatives to a gluten-free diet.

Probiotics Use in Celiac Disease: Results from a National Survey, the third study, is also currently being presented at ACG 2020 Virtual and is an Outstanding Poster Presenter recipient. Led by Andrew Joelson, MD, Gastroenterology Fellow at the Celiac Disease Center at Columbia University, the study examined probiotic use in the Foundation’s iCureCeliac® patient registry population finding that about one-third of patients reported using probiotics to treat persistent symptoms. Patients on a gluten-free diet who were still experiencing symptoms were twice as likely to use probiotics as patients who reported controlled symptoms. This is the Celiac Disease Foundation’s fifth collaboration with Dr. Joelson and his team at Columbia University since 2017 with iCureCeliac® data demonstrating the serious burden of celiac disease.

As always, we thank you for your generous support that makes our work possible.

To Our Health
Marilyn G. Geller, Chief Executive
For the latest information on celiac disease and
COVID-19, view our Resource Center.
Celiac Disease Foundation
20350 Ventura Boulevard | Suite 240
Woodland Hills, California 91364
818.716.1513
info@celiac.org

Download Tables, Images & References

MEDICAL BULLETIN BOARD

IBD Plexus®

Read Article

Academic Request for Proposals

The Crohn’s & Colitis Foundation has released a request for proposals (RFP) for academic researchers to gain access to IBD patients’ biosamples and/or research-ready datasets housed within IBD Plexus®.

IBD Plexus was founded by the Foundation to advance science, accelerate progress toward precision medicine, and improve the care of patients living with IBD. This first-of-its kind, national-scale, cloud-based platform integrates clinical, patient reported, genetic, and other molecular data from diverse research study cohorts, real-world clinical care settings, and patients’ experiences. IBD Plexus provides academic and industry researchers with access to research-ready datasets and biosamples to more rapidly perform activities that promise to speed treatment development, optimize existing therapies through development of biomarkers and diagnostics, and improve health outcomes.

IBD Plexus unites clinicians, scientists, educators, industry partners, and patients to answer questions that are critically important to advance the field of IBD research. The Foundation seeks research proposals that would utilize IBD Plexus biosamples and/or data to facilitate efforts in four main areas: identification and/or validation of diagnostics/biomarkers, therapeutic development and optimization, disease management, and disease prevention.

This is a rolling solicitation. The Foundation will continue to accept responses to the RFP until all awards are distributed.

For more information visit: crohnscolitisfoundation.org/PlexusRFP

Download Tables, Images & References

MEDICAL BULLETIN BOARD

Sebela Pharmaceuticals Receives Fda Approval for Sutab® Tablets for Colonoscopy Preparation

Read Article

SUTAB® Tablets with Active Sulfate Ingredients Give Gastroenterologists a New, Safe, and Effective Alternative to Liquid Bowel Preparations

BRAINTREE, MA — Sebela Pharmaceuticals® announces that the U.S. Food and Drug Administration (FDA) approved SUTAB® (sodium sulfate, magnesium sulfate, and potassium chloride) tablets. SUTAB, a sulfate-based tablet preparation for colonoscopy, was developed and will be marketed by Braintree Laboratories, the makers of SUPREP® Bowel Prep Kit (sodium sulfate, potassium sulfate and magnesium sulfate) Oral Solution—the market leader in branded colonoscopy preparations.1 SUTAB gives patients and physicians an alternative to liquidbased colonoscopy preparations. Braintree, a leader in gastroenterology, is part of Sebela Pharmaceuticals.

Colonoscopy is the most common detection method for colorectal cancer, a leading cause of cancer-related deaths that can be managed more effectively through screening.2 It is considered the gold standard of colorectal cancer screening methods for its ability to view the entire colon and both detect and remove polyps during the same procedure.3,4 Nineteen million colonoscopies are performed in the U.S. every year.5 For those patients, particularly those who have had difficulty completing colonoscopy preparation in the past, SUTAB presents a welcome alternative to liquid bowel preparation.

“Successful bowel prep is critical for gastroenterologists to clearly see any polyps or abnormalities, yet the immense volume of liquid prep solutions can prevent patients from adequately completing their regimens. Tablets provide a welcome alternative for successful prep completion and visualization of the colon,” said Douglas K. Rex, M.D., Director of Endoscopy at Indiana University Hospital and Professor, Department of Medicine, Division of Gastroenterology and Hepatology, University of Indiana School of Medicine.

Alan Cooke, President and CEO of Sebela Pharmaceuticals, said “Gastroenterologists and their patients have repeatedly asked for a safe and efficacious tablet bowel prep. Now patients can benefit from SUTAB, thanks to Braintree’s innovative and dedicated team, who have worked tirelessly to develop this important product. SUTAB’s FDA approval underscores Braintree’s more than thirtyfive year commitment to gastroenterology.”

In two pivotal trials, 92% of patients achieved successful bowel cleansing with SUTAB6 and 92%- 95% of patients achieved successful cleansing in all segments of the colon, including the proximal colon.7 In one pivotal trial, 91% of patients rated SUTAB as very easy to tolerable to consume.7 Seventyeight percent said they would request SUTAB again for a future colonoscopy.7 Fifty-two percent of all SUTAB and MoviPrep®8 patients reported at least one selected gastrointestinal adverse reaction.6 More SUTAB patients reported experiencing nausea and vomiting than comparator, with ≤1% of these reports considered severe.6

“The approval of SUTAB provides a welcome relief for patients who struggle with the unpleasant taste issues commonly associated with other products for colonoscopy preparation,” said Jack A. Di Palma, M.D., Professor of Medicine and Fellowship Program Director of the Division of Gastroenterology at the University of South Alabama College of Medicine and Past-President of the American College of Gastroenterology. “And because SUTAB contains the active sulfate ingredients similar to SUPREP, gastroenterologists will already be familiar with its effects.”

SUTAB will be available by prescription to patients in the U.S. on January 1, 2021.

Important Safety Information

SUTAB® (sodium sulfate, magnesium sulfate, potassium chloride) tablets for oral use is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults. DOSAGE AND ADMINSTRATION: A low residue breakfast may be consumed. After breakfast, only clear liquids may be consumed until after the colonoscopy. Administration of two doses of SUTAB (24 tablets) are required for a complete preparation for colonoscopy. Twelve (12) tablets are equivalent to one dose. Water must be consumed with each dose of SUTAB and additional water must be consumed after each dose. Complete all SUTAB tablets and required water at least 2 hours before colonoscopy. CONTRAINDICATIONS: Use is contraindicated in the following conditions: gastrointestinal obstruction or ileus, bowel perforation, toxic colitis or toxic megacolon, gastric retention. WARNINGS AND PRECAUTIONS: Risk of fluid and electrolyte abnormalities: Encourage adequate hydration, assess concurrent medications and consider laboratory assessments prior to and after each use; Cardiac arrhythmias: Consider predose and postcolonoscopy ECGs in patients at increased risk; Seizures: Use caution in patients with a history of seizures and patients at increased risk of seizures, including medications that lower the seizure threshold; Patients with renal impairment or taking concomitant medications that affect renal function: Use caution, ensure adequate hydration and consider laboratory testing; Suspected GI obstruction or perforation: Rule out the diagnosis before administration. ADVERSE REACTIONS: Most common gastrointestinal adverse reactions are: nausea, abdominal distension, vomiting and upper abdominal pain. DRUG INTERACTIONS: Drugs that increase risk of fluid and electrolyte imbalance.6 See Full Prescribing Information and Medication Guide

About SUTAB®

SUTAB® (sodium sulfate, magnesium sulfate, potassium chloride) tablets for oral use is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults. Cleaning the colon helps a healthcare provider see the inside of a colon more clearly during a colonoscopy.

Safety and effectiveness of SUTAB® in pediatric patients have not been established.6

About Sebela Pharmaceuticals®

Sebela Pharmaceuticals is a US-focused, growthoriented specialty pharmaceutical company developing and commercializing gastroenterology, women’s health, and dermatology prescription products. Braintree, a part of Sebela Pharmaceuticals, is a pioneer in gastroenterology therapy for bowel cleansing prior to colonoscopy having developed multiple innovative prescription bowel prep and constipation products including SUTAB®, SUPREP® Bowel Prep Kit, GoLYTELY® and NuLYTELY®. Our gastroenterology product line also includes Motofen®, Analpram HC® and recently approved Pizensy™ (indicated for chronic idiopathic constipation in adults). Sebela Pharmaceuticals has multiple further advances in bowel prep therapy in clinical development. Sebela Pharmaceuticals also has two next generation intra-uterine devices (IUDs) for contraception in development that hold the promise of a better patient experience in addition to excellent efficacy. Sebela Pharmaceuticals has offices in Roswell, GA; Braintree, MA; and Dublin, Ireland, has annual net sales of $200-250 million and has grown to over 300 employees through strategic acquisitions and organic growth.

References

  1. IQVIA. National Prescription Audit Report. September 2020.
  2. Doubeni CA, Corley DA, Quinn VP, et al. Effectiveness of screening colonoscopy in reducing the risk of death from right and left colon cancer: a large community-based study. Gut. 2018;67(2):291-298.
  3. Niederreiter M, Niederreiter L, Schmiderer A, Tilg H, Djanani A. Colorectal cancer screening and prevention—pros and cons. Memo. 2019;12;239-243.
  4. Stauffer CM, Pfeifer C. Colonoscopy. In: StatPearls. Treasure Island (FL): StatPearls Publishing; July 31, 2020. Accessed October 6, 2020.
  5. iData Research. An Astounding 19 Million Colonoscopies Are Performed Annually in The United States. https://idataresearch. com/an-astounding-19-million-colonoscopies-are-performedannually-in-the-unitedstates/. August 8, 2018. Accessed October 22, 2020.
  6. SUTAB® [package insert]. Braintree Laboratories, Inc., Braintree, MA: 2020.
  7. Di Palma JA, Bhandari R, Cleveland M, et al. A safety and efficacy comparison of a new sulfate-based tablet bowel preparation versus a PEG and ascorbate comparator in adult subjects undergoing colonoscopy. Am J Gastroenterol. Published online November 6, 2020. doi: 10.14309/ ajg.0000000000001020
  8. MoviPrep® (PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution) is a registered trademark of Velinor AG.

Download Tables, Images & References

FROM THE PEDIATRIC LITERATURE

Serologic Markers for Celiac Disease in Young Children

Read Article

Celiac disease (CD) is an autoimmune disease associated with small intestinal damage (villous atrophy and lymphocytic infiltration) in response to gluten ingestion. Although esophagogastroduodenoscopy (EGD) with duodenal biopsy is considered the “gold standard” test for confirming CD, the tissue transglutaminase IgA antibody titer (TTG IgA) is a highly sensitive and specific serum test for CD screening. National guidelines (such as from the Celiac Disease Foundation) do not recommend TTG IgA screening before 2 years of age because of concerns about testing sensitivity in that age group. The authors of this study tested this recommendation by reviewing medical records of children from 3 tertiary children’s hospitals in the United States. Two of the hospitals had retrospective records reviewed as far back as 20 years while the third hospital utilized a prospective database of children with villous atrophy diagnosed by EGD. All included patients were evaluated for diagnostic criteria for CD (including serologic markers of disease and duodenal biopsy findings), resolution of gastrointestinal symptoms on a gluten-free diet, and normalization of serologic markers for CD while on a gluten-free diet. Thus, patients with CD associated with positive serologic markers and positive duodenal biopsy findings were compared to a control group of children with duodenal biopsies consistent with CD but who had negative serologic findings and no gluten exposure or no response to a gluten-free diet.

A total of 150 children were included in the study for which 127 had CD and 23 belonged to the control group. The median age at time of duodenal biopsy was 18 months (range 3 – 24 months) with most children having a diagnosis of failure to thrive. Biopsies demonstrated intraepithelial lymphocytosis in 3% of children, partial villous atrophy in 45% of children, and total villous atrophy in 52% of children. Various CD serologic markers were ordered for these patients with TTG IgA being the most common test although other testing types included endomysium IgA, antigliadin IgA with / without IgG, and deamidated gliadin protein IgA with / without IgG. Of the 127 children with CD, 115 underwent TTG IgA testing for which 112 patients (97.5%) had elevated TTG IgA titers with the remaining 3 patients having positive TTG IgG titers. IgA deficiency was present in 5.5% of patients with CD although all such children had some type of positive IgG testing (such as TTG, anti-gliadin, or deamidated gliadin protein). Alternatively, 19 of the 23 children in the control group had TTG IgA testing performed, and all tests were negative. The remaining 4 children in the control group consisted of one patient with negative endomysium IgA testing and 3 children with no other serologic testing performed. When all patients with TTG IgA testing were compared, patients with CD were significantly older (19 months versus 15 months, P=0.001) and had a higher TTG IgA level (7.4 times the upper limit of normal versus 0.3 times the upper limit of normal, P<0.001).

This study, based on retrospective data, seems to indicate that TTG IgA testing may be an appropriate screen for CD in children younger than 2 years of age. The authors point out that IgG antibody testing may be indicated for those young patients with negative TTG IgA testing but with symptoms of CD.

Khan M, Silvester J, Sparks B, Hintze Z, Ediger T, Larson J, Hill I, Absah I. The utility of IgAbased serologic markers in diagnosing celiac disease in children 24 months of age or younger. Journal of Pediatrics 2020; 224: 158-161.

Download Tables, Images & References

MEDICAL BULLETIN BOARD

Compulink Readies EHR Coding Engine to Support E/M 2021 Changes

Read Article

Company’s EHR will help providers identify best codes to bill for maximum reimbursement

Newbury Park, CA – Compulink Healthcare Solutions, the creator of Advantage SMART Practice®, the EHR and practice management system powered by artificial intelligence (AI), has announced it is readying its EHR coding engine to support the new 2021 Evaluation and Management (E/M) CPT codes. Slated to become effective on January 1, 2021, the E/M changes are major and will impact coding and billing for every office visit.

To support E/M 2021, the company’s EHR coding engine will utilize the new coding methodology and time spent guidelines to automatically identify the best code to bill for maximum reimbursement. For its eyecare clients, Advantage will also automatically evaluate three possible eyecare codes and suggest the code with highest level of reimbursement.

“The last time the E/M coding underwent this major a revision was in the 1990s. These changes will have a huge impact on workflow and payment eligibility for our clients,” said Link PRACTICAL GASTROENTEROLOGY Celebrating Over 44 Years of Service practicalgastro.com Wilson, CEO and product architect for Compulink. “We’ve consulted with industry coding experts to help ensure providers will get paid the maximum amount for their services, and that we’re ready by the January deadline.”

The company also announced it is offering a money back guarantee to have its products ready to support the 2021 E/M changes.

Compulink’s Advantage SMART Practice, all-in-one database solution includes a specialtyspecific EHR, practice management, inventory management, patient engagement, ASC, E-commerce, and Optical POS (for eyecare practices). The company also provides an expert revenue cycle management service for its clients. Advantage is 2015 ONC Certified for MIPS. Compulink is used by more than 25,000 providers in over 4,700 locations, 60 ASCs, and 19 universities and colleges.

About Compulink Healthcare Solutions

A leader in specialty specific, all-in-one EHR and Practice Management solutions for 35 years, Compulink’s Advantage SMART Practice uses artificial intelligence to improve clinical and financial results.

Download Tables, Images & References

BOOK REVIEWS

The Little GI Book: An Easily Digestible Guide to Understanding Gastroenterology, 2nd Edition

Read Article

Author: Douglas G. Adler, MD, FACG, AGAF, FASGE
Publisher: SLACK Incorporated
Publication Year: 2020
ISBN-13: 978-1630917418
Book Price: $34.95

The Little GI Book: An Easily Digestible Guide to Understanding Gastroenterology is written by Dr. Douglas G. Adler, a tenured Professor of Medicine, director of therapeutic endoscopy and gastroenterology fellowship program director at the University of Utah School of Medicine. In the 2nd edition of this book, Dr. Adler includes the latest advances and changes in the diagnosis and treatment of many gastrointestinal (GI) disorders, while continuing his mission to create a simple, high-yield and enjoyable guide to the fundamentals of gastroenterology and hepatology.

This 280-page, pocket sized book is comprised of eight chapters separated by organ-specific diseases, including Esophagus, Stomach, Small Intestine, Colon and Rectum, Liver, Gallbladder and Bile Ducts, Pancreas and, finally, a general overview of endoscopes and endoscopy techniques such as colonoscopy, endoscopic retrograde cholangiopancreatography (ERCP), and endoscopic ultrasound (EUS), and other procedures. Each chapter generally begins with anatomy and physiology, and then delves into common organ-specific pathologies, which are often then sub-divided into pathophysiology, clinical presentation and, most importantly, the specialized diagnosis and treatment methods used by gastroenterologists. Throughout the text, there are numerous high-quality figures and color pictures of disease presentations visualized with endoscopy and endoscopic interventions results. Every chapter concludes with a list of references.

One of the core strengths of this book is its ability to create a window into the endoscopy suite, especially for individuals that have never stepped foot into one. In this book, there are pictures and descriptions of the types of endoscopic therapy used to treat a bleeding peptic ulcer, a common GI diagnosis, but also EUS images of a pancreatic mass surrounding the celiac artery and an explanation of how that position affects management. In addition, the benefit of the updated 2nd edition is the discussion of new advancements in the field of gastroenterology such as peroral endoscopy myotomy for the treatment of achalasia. This is not a textbook that covers the small details of the presentation, diagnosis, and management of every GI diagnosis, but instead, it focuses on providing a broad overview across the entire field of gastroenterology. This would not be the book to rely on for passing boards or shelf examinations; however, it is the ideal book for gaining practical, bedside knowledge to apply on any gastroenterology service. Overall, the combination of the book’s concise length, inclusion of the core GI diagnoses and friendly tone makes it an especially useful resource to resident physicians and upper-level medical students who desire a future in gastroenterology, as well as anyone who desires to have a strong foundation in gastroenterology.

Kevin Kurian, OMS-IV
UNT Health Science Center-Texas College of Osteopathic Medicine

Dawn Sears, MD, FACG
Chief of Gastroenterology
Baylor Scott and White Health
Temple, Texas
Twitter: @GutGirlMD

Download Tables, Images & References

FELLOWS’ CORNER

A Rare Differential: Afferent Limb Syndrome in Patients with an Ileal Pouch Anal Anastomosis

Read Article

CASE PRESENTATION

A 47-year-old male with a history of ulcerative colitis complicated by acute toxic colitis resulting in an emergent onestage laparoscopic restorative proctocolectomy with J-pouch formation, presented with a 10 -year history of intermittent gastrointestinal obstructive symptoms beginning after his operation. Additionally, he endorsed colicky abdominal pain, nausea, episodic vomiting, bloating, and acid reflux. His symptoms appeared shortly after his J-pouch was created without improvement over the next decade. Multiple cross-sectional imaging studies have been performed but failed to demonstrate any signs of obstruction with transition point, evidence of retained rectum or pouch twist, and no abdominal wall hernia or pelvic sepsis. He was referred to an inflammatory bowel disease surgeon where office exam was negative for paradox puborectalis and repeat endoscopy validated no pouch twist, retained rectum, anastomotic leak and the bowel proximal to his pouch was able to be visualized. A Gastrografin enema was performed which revealed normal pouch filling, however, after evacuation a large amount of contrast was present in the small bowel proximal to the pouch.

QUESTIONS

  1. What is the diagnosis in this patient?
  2. What is the underlying pathology of this syndrome?
  3. How is this syndrome diagnosed?
  4. What are the management options in this patient?

Question 1.

This patient is suffering from afferent limb syndrome (ALS) after restorative proctocolectomy, which is caused by an acute angulation of the afferent bowel at the pelvic pouch inlet (Image A). ALS differs from efferent limb syndrome (ELS) in patients with a pelvic pouch as ELS is caused by a long exit-conduit from an S-pouch, while ALS is caused by an obstruction proximal to the ilealanal pouch.

Question 2.

Restorative proctocolectomy and ileal pouch-anal anastomosis (IPAA) is the procedure of choice in patients who have ulcerative colitis, familial adenomatous polyposis, and select patients with Crohn’s disease.1 Despite a low failure rate of 3.4%, there are a variety of possible complications that can result in varying degrees of pouch dysfunction.2 Common postoperative complications are pelvic sepsis, hernia, pouch dysfunction due to inadvertent pouch-rectal anastomosis/pouch twists/outlet obstruction/paradoxical contraction, and the most common complication, small bowel obstruction (SBO).3 SBO in patients with an IPAA is frequently diagnosed by symptomatology and cross-sectional imaging and is a consequence of intra-abdominal adhesions, however, some patients with non-specific abdominal pain and bloating may have ALS. ALS can be due to acute angulation, intussusception of the distal ileum, or adhesions leading to obstruction of the afferent-limb at the bowel of the pouch inlet, typically with bowel trapped between the pouch and the sacrum.4 ALS is rare, occurring in just less than 2% of all patients after IPAA creation, and in 12% among patients who are displaying obstructive symptoms.4,5 ALS can present acutely after IPAA or years later.

Question 3.

ALS can present as abdominal pain, nausea, and vomiting, similar to symptoms of SBO, but without the typical radiographic findings seen with a bowel obstruction. Patients with ALS have often been worked up for various symptomatology, which typically begins with history, physical exam, and cross-sectional imaging of computed tomography (CT) to assess for adhesive small bowel obstruction. If the initial workup is negative, patients should undergo pouchoscopy to look for signs of Crohn’s disease or septic complications.

However, assuming symptoms are secondary to Crohn’s disease can lead to years of unneeded medical therapy when a mechanical issue needing corrective surgery is the underlying pathology. For this reason, the patient should be referred to a pouch specialist for formal workup. This includes an exam under anesthesia, flexible pouchoscopy to assess for pouch ulcers, a stricture at the pouch inlet or perianal fistulae to suggest Crohn’s disease/ pelvic sepsis, a pelvic magnetic resonance imaging to assess for retained rectum or pouch twist, and a Gastrografin enema (GGE) to assess for ALS or stricture. The typical finding for ALS of a GGE exam is contrast retention in a dilated pre-pouch small bowel after the patient has evacuated the Gastrografin (Image B).

Question 4.

The management of ALS involves a multidisciplinary team as endoscopic interventions and/or surgical management may be needed to correct the underlying obstruction at the pouch inlet. Endoscopic balloon dilation can be attempted, typically with a 20mm balloon, though almost half of patients require repeat dilations, and symptoms may continue to ultimately require operative intervention.4 Other endoscopic interventions such as needle-knife sinusotomy to divide the chronic scar at the angulated tissue have also had success.1 Surgically, patients can undergo resection of the angulated bowel with anastomosis, enteroenterostomy to bypass the segment adherent posteriorly to the pouch to avoid pouch mobilization (thus avoiding injury to the pouch or mesentery which can cause pouch ischemia), mobilization of the pouch with a pexy of the pouch and/or proximal small bowel, and pouch excision with the creation of an end-ileostomy.4 There is a 40-100% resolution of symptoms after surgical intervention, while around 40% of patients who undergo endoscopic interventions will need repeat endoscopic interventions.4,5 Though some series omit endoscopic interventions to correct ALS and refer the patient for surgery, endoscopic intervention by an experienced pouch-endoscopist may obviate the need for surgical intervention and should be attempted initially.4,5 This patient was able to undergo a laparoscopic adhesiolysis, abdominopelvic pouch mobilization, pouchopexy, and intraoperative pouchoscopy with diverting loop ileostomy. He was discharged uneventfully and able to tolerate a low-fiber diet without any abdominal pain or bloating. He underwent a GGE prior to stoma closure (Image C) which showed complete evacuation of the contrast from both his pouch and proximal small bowel. There were no further complaints of any abdominal pain or bloating after stoma closure.

CONCLUSION

Clinicians should be mindful when evaluating non-specific abdominal pain, bloating, or pouch dysfunction in patients who have undergone IPAA, as ALS can be elusive to diagnosis and so its presence must be germane during the workup. Complications such as afferent limb syndrome may be rare, however, may contribute to a delay in diagnosis in this patient population acutely or years after surgery. A multidisciplinary approach is necessary to properly identify the source of pathology and offer medical, endoscopic, or surgical correction.

References

  1. Holubar SD. Prevention, Diagnosis, and Treatment of Complications of the IPAA for Ulcerative Colitis. Dis Colon Rectum. 2018;61(5):532-536. doi:10.1097/ DCR.0000000000001094
  2. Delaney CP, Remzi FH, Gramlich T, Dadvand B, Fazio VW. Equivalent function, quality of life and pouch survival rates after ileal pouch-anal anastomosis for indeterminate and ulcerative colitis. Ann Surg. 2002;236(1):43-48. doi:10.1097/00000658-200207000-00008
  3. Ng K-S, Gonsalves SJ, Sagar PM. Ileal-anal pouches: A review of its history, indications, and complications. World journal of gastroenterology. World J Gastroenterol. Aug 21, 2019; 25(31): 4320-4342 doi: 10.3748/wjg.v25.i31.4320
  4. Read TE, Schoetz DJ, Marcello PW, et al. Afferent Limb Obstruction Complicating Ileal Pouch-Anal Anastomosis. Dis Col Rectum: May 1997 – p 566-569 doi: 10.1007/ BF02055380
  5. Kirat HT, Kiran RP, Remzi FH, Fazio VW, Shen B. Diagnosis and management of afferent limb syndrome in patients with ileal pouch-anal anastomosis. Inflamm Bowel Dis. 2011;17(6):1287-1290. doi:10.1002/ibd.21503

Download Tables, Images & References

A CASE REPORT

Dysphagia Aortica from Endovascular Leak After Thoracic Endovascular Aneurysm Repair

Read Article

Achalasia is an esophageal motility disorder that causes peristaltic dysfunction and failure of the lower esophageal sphincter (LES) to relax upon swallowing. Pseudoachalasia is a mimicker of achalasia, but its pathophysiology and treatments are different. We present a case of an elderly woman with dysphagia. Manometry was most consistent with type II achalasia. Ultimately, the diagnosis of dysphagia aortica causing pseudoachalasia from a large, compressing thoracic aorta endoleak after a thoracic endovascular aneurysm repair (TEVAR) was made. This diagnosis altered her management course, avoiding possible intervention such as peroral endoscopic myotomy (POEM) versus laparoscopic Heller myotomy (LHM).

INTRODUCTION

Achalasia is a primary esophageal neuromuscular motility disorder of unclear etiology.1 It results from degeneration of the myenteric plexus causing failure of the lower esophageal sphincter (LES) to relax upon swallowing with esophageal body dysmotility (absent contractility, panesophageal pressurization, or spastic contractions).1,2 In order to make the diagnosis of achalasia, it is crucial to rule out other mimickers including medication effect and pseudoachalasia in the appropriate patients.3 Dysphagia aortica (DA) is a rare cause of pseudoachalasia. First described in 1932 DA is due to external compression of the esophagus by ectatic, tortuous or aneurysmal thoracic aorta due to age related degeneration.4 It is mainly seen in elderly women of short stature and with co-existing conditions such as hypertension and kyphosis. We present a case of an elderly woman with manometric findings consistent with Type II achalasia who was transferred to our center for peroral endoscopic myotomy (POEM). After careful review of clinical history, imaging and manometry, her symptoms were more consistent with DA from a large, compressing thoracic aorta, resulting in pseudoachalasia.

Case Report

A 75-year-old woman with a history of antiJo1 antisynthetase syndrome, steroid dependent interstitial lung disease on home oxygen, chronic pain on long-term opiates, severe pulmonary hypertension, and thoracoabdominal aortic aneurysm status post total thoracic endovascular aneurysm repair (TEVAR) three years prior with recent redo presented with six months of worsening dysphagia to solids and progressing to liquids. This resulted in weight loss, failure to thrive, and recurrent aspiration with declining lung function.

Diagnostic work up included computed tomography (CT) scan which revealed active type II endoleak extending from the TEVAR with lateral compression and displacement of the esophagus (Figure A). Barium esophagram was subsequently performed that showed a delay in esophageal emptying with retrograde flow and evidence of a short segment narrowing at the lower esophageal sphincter (LES) where the TEVAR intersects the LES (Figure B). Upper endoscopy demonstrated esophageal candidiasis without evidence of stenosis, external compression, or tight LES. An endoscopically placed manometry catheter showed no normal peristalsis, panesophageal pressurization in 5/10 swallows, and an integrated relaxation pressure (IRP) of 25.4 (Figure C). After a multidisciplinary discussion with the therapeutic endoscopists, motility and neurogastroenterology specialists, and vascular surgeons, her clinical presentation was deemed most consistent with pseudoachalasia due to endovascular leak causing compression as opposed to primary achalasia, thus limiting the utility of therapy directed towards achalasia. Additionally, the risk of endovascular repair was felt to outweigh benefits.

The patient opted for conservative management of her dysphagia, which improved with treatment for esophageal candidiasis and dietary modification to liquids, and pureed foods. After a lengthy hospital stay, she wished to focus her attention on comfort, and she was discharged home with hospice care.

Discussion

Pseudoachalasia is a diagnostic entity that is indistinguishable from primary achalasia. Most reports are from a malignant paraneoplastic effect, or circumferential compression and infiltration of the LES.5,6 DA, itself, is an uncommon cause of dysphagia due to compression of the LES; however, DA resulting in pseudoachalasia is exceedingly rare. To date, there is only one case report of a patient initially thought to have achalasia but then found to have DA from a thoracic aortic aneurysm causing pseudoachalasia.5 To our knowledge, we believe we present the first reported case of a TEVAR endoleak causing pseudoachalasia.

This case posed a significant diagnostic challenge. Manometrically the patient’s diagnosis was that of type II achalasia. With the advent of high resolution manometry (HRM), achalasia can be separated into three subtypes (Type I, II and III) based upon the esophageal pressure topography and the Chicago Classification.1,2 Diagnosing the correct achalasia phenotype has important prognostic and therapeutic implications. For example, Type II achalasia, defined by absent peristalsis, an elevated IRP and panesophageal pressurization in a minimum of 2/10 reclining swallows, responds to pneumatic dilation, POEM, or Heller myotomy.3

Our patient was a high risk surgical or POEM candidate due to her known cardiopulmonary disease, chronic steroids use, and position of the active endovascular leak near the LES; however, there were multiple factors that made her achalasia diagnosis questionable. First, opiates have been shown to cause dysphagia and manometry findings comparable to achalasia.7 Once opiates are stopped, esophageal motility returns to normal. For our patient, ceasing all opiate use would have resulted in significant morbidity and thus was a last resort. Secondly, her history was more consistent with pseudoachalasia: sudden onset of symptoms, marked weight loss, and an esophageal compression at the site of the endovascular leak.

DA is a rare cause of pseudoachalasia, and thus little is known about the underlying pathophysiology. This external compression may result in esophageal dysmotility based on the anatomic impact of the vasculature on the esophagus.8 In our patient it was the compression by the TEVAR and endoleak that was the most likely cause of her DA and subsequent pseudoachalasia. There was the additional confounder of chronic opioid use that cannot be ignored as a possible contributing factor; however, this would not account for the radiographic findings.

This case highlighted the importance of distinguishing pseudoachalasia from primary achalasia, as treatment options are different. Treatment for pseudoachalasia is aimed at the primary cause. In our case, this would be directed towards weaning off opiates and endovascular repair, for which the latter was deemed to be high risk with uncertain benefit. Achalasia is managed taking into account a number of factors including sex, age, subtype of achalasia, and patient preference with the management choices being laparoscopic Heller myotomy, pneumatic dilation, hydrostatic dilation, POEM, or botulinum toxin injection. To help differentiate pseudoachalasia from true achalasia, amyl nitrate could have been administered during manometry, resulting in LES relaxation in the latter. Unfortunately, this diagnostic option was considered too dangerous for our patient given her severe cardiopulmonary disease. This case highlights the importance of a thorough review of patients’ history and clinical presentation in combination with a multidisciplinary approach to decipher the true cause of dysphagia to most appropriately manage complex esophageal disease.

References

  1. Pandolfino JE, Gawron AJ. Achalasia: a systematic review. Jama. 2015;313(18):1841-1852.
  2. Kahrilas PJ, Bredenoord AJ, Fox M, et al. The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil. 2015;27(2):160-174.
  3. Khashab MA, Vela MF, Thosani N, et al. ASGE guideline on the management of achalasia. Gastrointest Endosc. 2019.
  4. Wilkinson JM, Euinton HA, Smith LF, Bull MJ, Thorpe JA. Diagnostic dilemmas in dysphagia aortica. Eur J Cardiothorac Surg. 1997;11(2):222-227.
  5. Beqari J, Lembo A, Critchlow J, Hamden A, Kent MS. Pseudoachalasia Secondary to Thoracic Aortic Aneurysm. Ann Thorac Surg. 2017;103(6):e517-e518.
  6. Gockel I, Eckardt VF, Schmitt T, Junginger T. Pseudoachalasia: a case series and analysis of the literature. Scand J Gastroenterol. 2005;40(4):378-385.
  7. Ratuapli SK, Crowell MD, DiBaise JK, et al. Opioid-Induced Esophageal Dysfunction (OIED) in Patients on Chronic Opioids. Am J Gastroenterol. 2015;110(7):979-984. 8. Mucklow EH, Smith OE. Dysphagia and unusual radiographic appearances associated with the variable relationships of the aorta and lower oesophagus. J Fac Radiol. 1954;6(2):88-95.

Download Tables, Images & References

Jojobet GirişmatbetcasibomcasibomcasibomGrandpashabetgrandpashabetcasibom girişCasibomcasibommavibetcasibomMeritkingGrandpashabetCasibomgrandpashabetcasibombetpasjojobet girişjojobetKickmavibetmatbetcasibominterbahisMadridbetMadridbetMadridbetJojobetgrandpashabetHoliganbet girişgrandpashabetJojobetcasibomgrandpashabetjojobetcasibomjojobetjojobetcasibomcasibom girişgrandpashabetholiganbetBetpasgrandpashabet güncel girişjojobetjojobet girişgrandpashabet